Ipamorelin side effects by evidence tier: the intravenous Phase 1 and Phase 2 tolerability data, rodent findings, GH-secretagogue class effects, the gaps, and Canadian and WADA status.
Ipamorelin is a five-amino-acid growth hormone secretagogue — a selective ghrelin-receptor agonist — that went through early-phase human trials at Novo Nordisk before development stopped. That history matters: unlike most research peptides, ipamorelin has a small amount of controlled human tolerability data, but it was collected by the intravenous route over days, not the subcutaneous route over months. This page is a research reference that keeps the evidence tiers apart — trials, animal work, class pharmacology, uncontrolled self-report. It is not advice.
The Ipamorelin profile is the reference entry; the ipamorelin research overview covers the receptor mechanism, and the ipamorelin dosage notes summarise how the studies administered it.
Two human datasets exist, both intravenous and both short.
Pharmacokinetic study, healthy volunteers. Gobburu and colleagues (Pharmaceutical Research, 1999) gave ascending intravenous doses of roughly 1 to 100 mcg/kg to healthy male volunteers, eight per dose level, and modelled the GH response. The study reported no significant adverse effects at the doses tested. Its pharmacology frames everything else: a terminal half-life of about two hours, a single GH pulse peaking within the first hour, and a dose-proportional response.
Phase 2, postoperative ileus. Beck and colleagues (International Journal of Colorectal Disease, 2014; NCT00672074) randomised patients recovering from bowel resection to intravenous ipamorelin at 0.03 mg/kg twice daily or placebo, for up to seven days after surgery. The trial was terminated for insufficient efficacy on its motility endpoint, but its tolerability finding is the most useful human safety statement that exists: ipamorelin was described as well tolerated, with an adverse-event profile similar to placebo. Two qualifications apply. The population was surgical, so background events were common in both arms and a drug-specific signal would be hard to see. And seven days is the longest any person has received ipamorelin in a published study.
Selectivity as a safety-adjacent finding. Raun and colleagues (European Journal of Endocrinology, 1998) showed GH release in rats and pigs with no ACTH or cortisol release even at doses two hundred times the GH-releasing ED50, and later human work confirmed a minimal cortisol and prolactin response compared with GHRP-2 and GHRP-6. That removes the stress-hormone effects of the older GHRPs from the expected profile — a finding about which effects are absent, not that the remaining ones are harmless.
The Novo Nordisk rodent programme — longitudinal bone growth (Growth Hormone & IGF Research, 1999), the glucocorticoid bone-formation study (2001) and the postoperative-ileus model (Journal of Pharmacology and Experimental Therapeutics, 2009) — used subcutaneous or intravenous doses in the tens to hundreds of micrograms per kilogram. The published record does not raise toxicology flags, and body-weight and lean-mass increases were reported as pharmacology rather than adverse findings. That covers a few weeks in rodents; it says little about chronic exposure in another species by another route.
Every growth hormone secretagogue acting at the ghrelin receptor shares a set of expected effects, and applied research with ipamorelin describes the same ones: transient flushing and headache after dosing, mild water retention, a modest increase in appetite, and, with repeated dosing, a fall in the GH response as the pituitary adapts. That tachyphylaxis is documented for the GHRP class generally, not measured for ipamorelin in a controlled study.
The larger questions sit downstream. Ipamorelin raises GH, and GH raises IGF-1, so the theoretical concerns attached to growth hormone follow: reduced insulin sensitivity with sustained exposure, and the possibility that elevated IGF-1 could promote an existing tumour. Neither has been demonstrated for ipamorelin; neither has been studied long enough to be ruled out. Pituitary feedback bounds the GH rise, which is an argument for a more physiological profile than injected GH — not a measured safety margin.
The published record supports a narrow statement: intravenous ipamorelin was well tolerated in healthy men for single doses and in surgical patients for a week. It says nothing controlled about:
Community and vendor sources add injection-site redness, drowsiness after evening dosing, hunger and water retention — uncontrolled, unblinded reports with no denominator, which cannot establish incidence, causation or severity.
Some share of the reactions reported in unregulated peptide use plausibly traces to the vial rather than the molecule: synthesis impurities, endotoxin load, or material degraded by a broken cold chain. Ipamorelin itself is chemically robust, but in the pre-mixed blend the CJC-1295 component is the more fragile of the two and sets the shelf life; the cold-chain and shelf-life guide covers the handling rules. Third-party HPLC purity and mass-spectrometry identity are the only way to separate compound effects from product effects — see lab testing and COAs and reading a peptide certificate of analysis.
Ipamorelin has no Health Canada market authorisation and no DIN, and the standalone research-grade ipamorelin sold here is supplied for laboratory research only. In September 2023 the U.S. FDA placed ipamorelin in category 2 of its section 503A bulk-substance evaluation, citing the absence of adequate human safety data, so it may not be used in compounded medicines there. The World Anti-Doping Agency lists growth hormone secretagogues under S2 and names ipamorelin explicitly; it is prohibited for tested athletes at all times.
Does ipamorelin have a documented side-effect profile? A short one. Two intravenous human studies — the 1999 pharmacokinetic study in healthy men and the 2014 Phase 2 trial in bowel-resection patients — reported no significant adverse effects and a placebo-like adverse-event profile respectively. There is no controlled safety data for subcutaneous or long-term use.
What did the Phase 2 trial report? Beck et al. (2014; NCT00672074) gave 0.03 mg/kg intravenously twice daily for up to seven days after surgery and described ipamorelin as well tolerated with an adverse-event profile similar to placebo. The trial was stopped for lack of efficacy, not for safety reasons.
Does ipamorelin raise cortisol or prolactin? Not measurably in the published work. Raun et al. (1998) found no ACTH or cortisol release in rats and pigs, and human comparisons reported a minimal cortisol and prolactin response relative to GHRP-2 and GHRP-6. That selectivity is the compound's defining feature.
Is the IGF-1 and cancer concern established? No, and neither is its absence. Any compound that raises GH raises IGF-1, and IGF-1 is mitogenic. No ipamorelin study has been long or large enough to test the question, and the FDA cited that absence of human safety data in its 2023 compounding determination.
Is ipamorelin prohibited in sport? Yes. WADA's Prohibited List names ipamorelin under S2, growth hormone secretagogues, prohibited at all times.
Is this medical advice? No. This page summarises published research for laboratory reference. Ipamorelin is sold here as a research-grade material, not for human or veterinary use, and nothing above is a safety assurance or a dosing recommendation. Health decisions belong with a qualified physician.
